1. Home
  2. NWL vs NUVB Comparison

NWL vs NUVB Comparison

Compare NWL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newell Brands Inc.

NWL

Newell Brands Inc.

HOLD

Current Price

$0.00

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.41

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWL
NUVB
Founded
1903
2018
Country
United States
United States
Employees
N/A
291
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
NWL
NUVB
Price
N/A
$4.41
Analyst Decision
Strong Buy
Analyst Count
8
Target Price
N/A
$11.38
AVG Volume (30 Days)
N/A
3.6M
Earning Date
04-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$190.15
Revenue Next Year
N/A
$62.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.57
52 Week High
N/A
$9.75

Technical Indicators

Market Signals
Indicator
NWL
NUVB
Relative Strength Index (RSI) 34.23 43.80
Support Level $3.33 $4.07
Resistance Level $3.51 $5.55
Average True Range (ATR) 0.17 0.21
MACD -0.01 0.07
Stochastic Oscillator 14.81 62.39

Price Performance

Historical Comparison
NWL
NUVB

About NWL Newell Brands Inc.

Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: